Cargando…

Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives

Visual acuity is a key outcome measure in the treatment of neovascular age-related macular degeneration (nAMD) using anti-vascular endothelial growth factor agents. Large variations in visual responses between individuals within clinical trials and real-world studies may relate to underlying differe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phan, Long T, Broadhead, Geoffrey K, Hong, Thomas H, Chang, Andrew A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364912/ https://www.ncbi.nlm.nih.gov/pubmed/34408393 http://dx.doi.org/10.2147/OPTH.S205147

Ejemplares similares

The burden of neovascular age-related macular degeneration: a patient’s perspective
por: Spooner, Kimberly L, et al.
Publicado: (2018)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
por: Joshi, Shrinivas, et al.
Publicado: (2023)

Functional Visual Acuity in Age-Related Macular Degeneration
por: Tomita, Yohei, et al.
Publicado: (2016)

Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity
por: Feigl, Beatrix, et al.
Publicado: (2007)

Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
por: Chakravarthy, Usha, et al.
Publicado: (2020)

Predictive value of pigment epithelial detachment markers for visual acuity outcomes in neovascular age-related macular degeneration
por: Shu, Yiyang, et al.
Publicado: (2023)

Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration
por: Zhang, Xinyuan, et al.
Publicado: (2018)

Modelling Cost Effectiveness in Neovascular Age-Related Macular Degeneration: The Impact of Using Contrast Sensitivity vs. Visual Acuity
por: Butt, Thomas, et al.
Publicado: (2014)

Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
por: Mulyukov, Zufar, et al.
Publicado: (2018)

Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration
por: Abbas, Abdallah, et al.
Publicado: (2022)

Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
por: Fang, Kai, et al.
Publicado: (2013)

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
por: Holz, Frank G, et al.
Publicado: (2016)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

Mental health and visual acuity in patients with age-related macular degeneration
por: Fonteh, Cheryl N., et al.
Publicado: (2022)

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
por: Wachtlin, Joachim, et al.
Publicado: (2020)

Relationships of orientation discrimination threshold and visual acuity with macular lesions in age-related macular degeneration
por: Fu, Haojie, et al.
Publicado: (2017)

Effect of Phacoemulsification on Visual Acuity and Macular Morphology in Patients with Wet Age-Related Macular Degeneration
por: Figurska, Małgorzata, et al.
Publicado: (2018)

Treatment of neovascular age-related macular degeneration: Current therapies
por: Augustin, Albert J, et al.
Publicado: (2009)

Relevance of Visual Acuity Measurement for Therapeutic Decisions in Age-Related Macular Degeneration
por: Mathis, Thibaud, et al.
Publicado: (2023)

Treatment of age-related neovascular macular degeneration: the patient’s perspective
por: Müller, S., et al.
Publicado: (2017)

Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration
por: Roberts, Philipp K., et al.
Publicado: (2022)

Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study
por: Elshout, Mari, et al.
Publicado: (2017)

The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results
por: Stattin, Martin, et al.
Publicado: (2021)

A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea
por: Kim, Jae Hui, et al.
Publicado: (2022)

Outer nuclear layer recovery as a predictor of visual prognosis in type 1 choroidal neovascularization of neovascular age-related macular degeneration
por: Lee, Seungheon, et al.
Publicado: (2023)

Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis
por: Chaudhary, Varun, et al.
Publicado: (2022)

Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives
por: Tenbrock, Louis, et al.
Publicado: (2021)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Socioeconomic status and visual outcome in patients with neovascular age-related macular degeneration
por: Levinger, Nadav, et al.
Publicado: (2020)

Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
por: El Matri, Leila, et al.
Publicado: (2012)

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
por: Koch, Raphael, et al.
Publicado: (2015)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi, Hidenori, et al.
Publicado: (2018)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
por: ElSheikh, Reem H., et al.
Publicado: (2022)

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study
por: Staurenghi, Giovanni, et al.
Publicado: (2021)

Correlation of macular sensitivity measures and visual acuity to vision-related quality of life in patients with age-related macular degeneration
por: Forshaw, Thomas Richard Johansen, et al.
Publicado: (2021)

VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iu183pb90us40jiktl97rhksmq